| References: |
cyclo(-RGDfK,-Arg-Gly-Asp-D-Phe-Lys)) is a selective αvβ3-integrin antagonist. In one study where this peptide was labeled with 125I, it was found to bind specifically and with high affinity to αvβ3 receptors on neovascular blood vessel sections of different major human cancers. The integrin alpha(IIb)beta(3)-specific cyclic hexapeptide contains an Arg-Gly-Asp (RGD) sequence. For the detailed information of cyclo(-RGDfK), the solubility of cyclo(-RGDfK) in water, the solubility of cyclo(-RGDfK) in DMSO, the solubility of cyclo(-RGDfK) in PBS buffer, the animal experiment (test) of cyclo(-RGDfK), the cell expriment (test) of cyclo(-RGDfK), the in vivo, in vitro and clinical trial test of cyclo(-RGDfK), the EC50, IC50,and affinity,of cyclo(-RGDfK), For the detailed information of cyclo(-RGDfK), the solubility of cyclo(-RGDfK) in water, the solubility of cyclo(-RGDfK) in DMSO, the solubility of cyclo(-RGDfK) in PBS buffer, the animal experiment (test) of cyclo(-RGDfK), the cell expriment (test) of cyclo(-RGDfK), the in vivo, in vitro and clinical trial test of cyclo(-RGDfK), the EC50, IC50,and affinity,of cyclo(-RGDfK), Please contact DC Chemicals. |
